|
1
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group. Comparison of four chemotherapy
regimens for advanced Non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced Non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323.
2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kanaji N, Mizoguchi H, Inoue T, Tadokoro
A, Watanabe N, Ishii T, Tojo Y, Yamaguchi M and Kadowaki N:
Clinical features of patients with lung cancer accompanied by
thromboembolism or disseminated intravascular coagulation. Ther
Clin Risk Manag. 14:1361–1368. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Van de Ven M, Retèl VP, Koffijberg H, van
Harten WH and IJzerman MJ: Variation in the time to treatment for
stage III and IV non-small cell lung cancer patients for hospitals
in the Netherlands. Lung Cancer. 134:34–41. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kawahara M, Furuse K, Segawa Y, Yoshimori
K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-1 Cooperative
Study Group (Lung Cancer Working Group). Phase II study of S-1, a
novel oral fluorouracil, in advanced non-small-cell lung cancer. Br
J Cancer. 85:939–943. 2001.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yoshioka H, Okamoto I, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, et al:
Efficacy and safety analysis according to histology for S-1 in
combination with carboplatin as First-line chemotherapy in patients
with advanced Non-small-cell lung cancer: Updated results of the
West Japan Oncology Group LETS study. Ann Oncol. 24:1326–1331.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yamamoto N, Tamura T, Kurata T, Yamamoto
N, Sekine I, Kunitoh H, Ohe Y and Saijo N: A dose-finding and
pharmacokinetic study of nedaplatin in elderly patients with
advanced non-small cell lung cancer. Cancer Chemother Pharmacol.
65:79–88. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kodaira T, Fuwa N, Tachibana H and Hidano
S: Phase I study of S-1 and nedaplatin for patients with recurrence
of head and neck cancer. Anticancer Res. 26:2265–2268.
2006.PubMed/NCBI
|
|
9
|
Kogashiwa Y, Yamauchi K, Nagafuji H,
Matsuda T, Tsubosaka T, Karaho T, Maruyama T and Kohno N: Phase I
study of S-1 plus nedaplatin in patients with advanced/recurrent
head and neck cancer. Chemotherapy. 56:453–458. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yokoi T, Minami S, Shiroyama T, Koba T,
Torii Y, Sugimoto H, Niki M, Mori M, Morimura O, Hirashima T, et
al: A Phase II study of Tailored-dose S-1 plus carboplatin followed
by maintenance S-1 for advanced squamous cell lung cancer:
OSAKA-LCSG 1102. Intern Med. 58:1405–1410. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shukuya T, Yamanaka T, Seto T, Daga H,
Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, et al:
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for
advanced or relapsed squamous cell carcinoma of the lung
(WJOG5208L): A randomised, open-label, phase 3 trial. Lancet Oncol.
16:1630–1638. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tang Y, Wang W, Teng XZ and Shi L:
Efficacy of S-1 plus nedaplatin compared to standard second-line
chemotherapy in EGFR-negative lung adenocarcinoma after failure of
first-line chemotherapy. Tumour Biol. 35:8945–8951. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Thatcher N, Hirsch FR, Luft AV, Szczesna
A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy
G, et al: Necitumumab plus gemcitabine and cisplatin versus
gemcitabine and cisplatin alone as first-line therapy in patients
with stage IV squamous non-small-cell lung cancer (SQUIRE): An
open-label, randomised, controlled phase 3 trial. Lancet Oncol.
16:763–774. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Watanabe S, Yoshioka H, Sakai H, Hotta K,
Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K,
et al: Necitumumab plus gemcitabine and cisplatin versus
gemcitabine and cisplatin alone as first-line treatment for stage
IV squamous non-small cell lung cancer: A phase 1b and randomized,
open-label, multicenter, phase 2 trial in Japan. Lung Cancer.
129:55–62. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell
Lung Cancer. N Engl J Med. 379:2040–2051. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mazieres J, Kowalski D, Luft A, Vicente D,
Tafreshi A, Gümüş M, Laktionov K, Hermes B, Cicin I, Rodríguez-Cid
J, et al: Health-related quality of life with
carboplatin-paclitaxel or nab-Paclitaxel with or without
pembrolizumab in patients with metastatic squamous non-small-cell
lung cancer. J Clin Oncol. 38:271–280. 2020.PubMed/NCBI View Article : Google Scholar
|
